CaMKIIα Signaling Is Required for the Neuroprotective Effects of Dl-3-n-Butylphthalide in Alzheimer’s Disease

• DOI: 10.1007/s12035-022-02777-8
• Publication Date: 2022-03-19T15:05:36Z
• Authors: Bing-qiu Li; Ling-zhi Xu; Fang-yu Li; Ying Li; Yu Zhao; Heng Zhang; Mei-na Quan; Jian-ping Jia
• Keywords: 0303 health sciences; 03 medical and health sciences; Neuroprotective Agents; Alzheimer Disease; Humans; Neurodegenerative Diseases; Benzofurans; 3. Good health

Alzheimer's disease (AD) is the most common form of neurodegenerative disease and most anti-AD drugs have failed in clinical trials; hence, it is urgent to find potentially effective drugs against AD. DL-3-n-butylphthalide (NBP) is a compound extracted from celery seed and is a multiple-target drug. Several studies have demonstrated the neuroprotective effects of NBP on cognitive impairment, but the mechanisms of NBP remains relatively unexplored. In this study, we found that NBP could alleviated the increase of intracellular Ca2+ and reversed down-regulation of Ca2+/calmodulin-dependent protein kinase alpha (CaMKIIα) signaling and rescued neuronal apoptosis in SH-SY5Y cells treated by Aβ oligomers. However, these neuroprotective effects of NBP on neuronal damage and CaMKIIα signaling were abolished when CaMKIIα expression was knocked down or its activity was inhibited. Thus, our findings suggested that CaMKIIα signaling was required for the neuroprotective effects of NBP in AD and provided an improved basis for elucidating the mechanism and treatment of NBP in AD.